Stay updated with breaking news from Erik Wallstr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.
Sanofi's anti-CD40L antibody frexalimab demonstrated reduced disease activity in a Phase II trial of patients with relapsing multiple sclerosis (RMS).
Frexalimab, a second-generation CD40L blocker, safely reduced the number of new active brain lesions in relapsing MS patients in a Phase 2 trial.
Disease activity in relapsing MS patients significantly fell following treatment with frexalimab, a novel second-generation investigational anti-CD40L antibody developed by Sanofi, according to a company press release.
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary